

*Accepted as oral presentation #OC4 at the World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, April 19-22, 2018, Krakow, Poland*

## **Results from a 52 Week, Phase 2a Study of an Intra-Articular, Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis**

Yusuf Yazici<sup>1</sup>, Timothy E. McAlindon<sup>2</sup>, Allan Gibofsky<sup>3</sup>, Nancy E. Lane<sup>4</sup>, Daniel J. Clauw<sup>5</sup>, Christopher J. Swearingen<sup>1</sup>, Anita DiFrancesco<sup>1</sup>, Jeyanesh R.S. Tambiah<sup>1</sup>, and Marc Hochberg<sup>6</sup>

<sup>1</sup>Samumed, LLC, San Diego, CA, USA

<sup>2</sup>Tufts Medical Center, Boston, MA, USA

<sup>3</sup>Hospital for Special Surgery, New York, NY, USA

<sup>4</sup>UC Davis Medical Center, Davis, CA, USA

<sup>5</sup>University of Michigan, Ann Arbor, MI, USA

<sup>6</sup>University of Maryland School of Medicine, Baltimore, MD, USA


**Objective:** Wnt signaling is upregulated in osteoarthritis (OA) and involved in cartilage degradation. SM04690 is a small molecule Wnt pathway inhibitor in development as a potential disease modifying osteoarthritis drug for knee OA. A phase 2a study was conducted to identify a target population and optimize dose. The primary endpoint was change from baseline in WOMAC Pain at Week 13. Secondary endpoints included change from baseline in WOMAC Pain, Function and change in radiographic medial compartment joint space width (mJSW) at Week 52.

**Material and methods:** Kellgren-Lawrence (KL) grades 2-3 knee OA subjects received a single 2 mL injection of SM04690 0.03 mg, 0.07 mg, 0.23 mg or saline (PBO) in their target (most painful) knee. WOMAC Pain and Function subscores were measured at Weeks 0, 4, 13, 26, 39 and 52. Knee radiographs (PA, weight-bearing, positioned) were taken at Weeks 0, 26, 52. Analysis of covariance adjusted for baseline with multiple imputation in the intent-to-treat (ITT) population and a pre-specified subgroup analysis of subjects with unilateral symptoms (US subgroup) were performed.

**Results:** 455 subjects (mean age 60.3 [ $\pm$ 8.7], BMI 29.9 [ $\pm$ 4.6] kg/m<sup>2</sup>, female 58.9%, KL 3 [64.4%], US [36.0%]) were enrolled. SM04690 appeared well tolerated and incidence of adverse events was similar in active and PBO groups. In ITT, minimum clinically important differences (>10% range) from baseline were seen in all WOMAC subscores at all timepoints, but these changes in active treatment arms were not significant compared to PBO. In the US subgroup (n=164), 0.07 mg SM04690 showed statistically significant improvements in WOMAC Pain (-4.4,  $P=0.049$ ), WOMAC Function (-17.5,  $P=0.035$ ) and mJSW (0.39 mm,  $P=0.021$ ) at Week 52 compared to PBO (Figure).

**Conclusions:** While the primary endpoint was not met, in a target population of subjects with unilateral symptoms treated with SM04690, WOMAC Pain, WOMAC Function, and mJSW were significantly improved over PBO. Further investigation of the 0.07 mg SM04690 unilateral symptomatic population is warranted.

**Improvement of SM04690 over Placebo**



†Minimal clinically important difference (MCID) defined as 10% of WOMAC Pain scale, or 5 points. ‡MCID defined as 10% of WOMAC Function scale, or 17 points. §Minimum detectable difference (MDD) defined as 0.13 mm of mJSW.